• Engineering bispecific antibody degraders to enable selective, lysosomal degradation of target membrane proteins
• Pairing therapeutic targets with membrane E3 ligases to achieve tissue-specific degradation while sparing healthy tissues
• Expanding therapeutic reach to hard-to-drug and challenging membrane targets

New Data